1. Epigenetics in Prostate Cancer: Biologic and Clinical Relevance
Carmen Jerónimo, Patrick J. Bastian, Anders Bjartell, Giuseppina M. Carbone, James W.F. Catto, Susan J. Clark, Rui Henrique, William G. Nelson, Shahrokh F. Shariat 
European Urology 
Volume 60, Issue 4, Pages (October 2011)
DOI: /j.eururo
Copyright © 2011 European Association of Urology Terms and Conditions

2. Fig. 1
Schematic overview of the crosstalk between ETS–polycomb group proteins and ETS–miRNA in prostate cancer.
ESC=embryonic stem cell; AR=androgen receptor
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

3. Fig. 2
Epigenetic biomarkers in prostate cancer (PCa) management. From the published data, specific sets of informative biomarkers were chosen for cancer detection (EpiTest 1), as ancillary tools to histopathologic observation (EpiTest 2), pretherapeutic prediction of prognosis and tumor aggressiveness (EpiTest 3), and prediction of recurrence and progression following radical prostatectomy (EpiTest 4). Meth refers to quantitative DNA methylation analysis; histone modifications and expression of histone modifiers are assessed by immunohistochemistry; microRNA expression is assessed by quantitative reverse-transcriptase polymerase chain reaction.
PCa=prostate cancer
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions